Physician profile
Daniel Pomposini
NPI 1992740294
$5,493.49
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $1,027 · 2021: $1,414 · 2022: $894 · 2023: $397 · 2024: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $799.63 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $698.04 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $678.84 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $518.98 | 2019-2024 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $374.21 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $312.06 | 2019-2022 | |
| Lilly USA, LLC | $284.44 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.82 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $254.22 | 2019-2022 | |
| Esperion Therapeutics, INC. | $217.26 | 2020-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $197.11 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.93 | 2021-2024 | |
| Pfizer INC. | $136.39 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.74 | 2023 | |
| Arbor Pharmaceuticals, INC. | $58.69 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $57.33 | 2019-2023 | Rexulti |
| Biogen, INC. | $50.39 | 2021-2022 | |
| Lundbeck LLC | $47.55 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $40.07 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $39.24 | 2019-2022 | |
| Genentech USA, INC. | $36.28 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.21 | 2021-2022 | |
| Allergan, INC. | $33.95 | 2020 | |
| Sunovion Pharmaceuticals INC. | $32.58 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $24.91 | 2021 | |
| Corcept Therapeutics | $20.86 | 2024 | Korlym |
| Glaxosmithkline, LLC. | $14.01 | 2023 | Shingrix, Arexvy |
| Currax Pharmaceuticals LLC | $13.75 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pomposini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.